Viking Therapeutics (VKTX) will initiate Phase 3 trials for its oral weight-loss candidate VK2735 in the fourth quarter, following an end-of-phase 2 meeting with the Food and Drug Administration. The drug activates GLP-1 and GIP receptors, the same mechanism Eli Lilly uses in Zepbound.

Here's the problem: the oral formulation has a tolerability ceiling that will limit its market potential.

In Phase 2, VK2735 oral achieved 12.2 percent body weight loss over 13 weeks versus 1.3 percent for placebo. That efficacy signal is real. But 20 percent of patients discontinued due to side effects, compared to 13 percent in the placebo arm. In the highest-dose cohort, discontinuation hit 38 percent—a red flag.

Viking claims Phase 3 doses show no meaningful difference from placebo in gut side effects. That statement contradicts the Phase 2 data, which showed a clear dose-response relationship: more weight loss came with more tolerability problems. Translation: the doses that work are the doses patients won't tolerate.

Eli Lilly's oral Foundayo sets the competitive benchmark. Over 72 weeks, it delivered 11.1 percent weight loss versus 2.1 percent for placebo, with discontinuation rates of 5 to 10 percent due to side effects. That's a vastly superior tolerability profile. Viking's Phase 2 trial was only 13 weeks—a quarter the duration of Foundayo's key trial. Extrapolating VK2735's discontinuation trajectory over 72 weeks suggests the oral candidate will struggle to differentiate.

The injectable VK2735 is where VKTX has a genuine edge.

In Phase 2, weekly injectable shots produced 14.7 percent body weight loss after 13 weeks, outpacing the oral version. A Phase 1 subset receiving weekly 17.5-mg injections for 33 weeks achieved 21.7 percent weight loss. More compelling: patients who switched to monthly dosing maintained 90 percent of their weight loss over 12 weeks, versus 61 percent for placebo.

A monthly injection regimen could be a meaningful differentiation point against Lilly's weekly Zepbound. But Viking's Phase 3 for the injectable is testing weekly dosing only, not monthly. Phase 3 completion is scheduled for July 2027.

The investment thesis hinges on that July 2027 injectable Phase 3 readout. If it mirrors Phase 2 data—which showed superior efficacy and presumably better tolerability than the oral—VKTX has a viable commercial product. The oral VK2735, despite advancing to Phase 3, is unlikely to capture meaningful share against Foundayo's established efficacy and tolerability profile.

Watch the injectable Phase 3 timeline. That's where VKTX creates or destroys shareholder value.